Comparative Pharmacology
Head-to-head clinical analysis: CIMZIA versus HADLIMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIMZIA versus HADLIMA.
CIMZIA vs HADLIMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Certolizumab pegol is a recombinant, humanized antibody Fab' fragment conjugated to polyethylene glycol (PEG) that binds and neutralizes human tumor necrosis factor alpha (TNFα), preventing its interaction with cell surface TNF receptors (TNFR p55 and p75). It also modulates immune responses by inhibiting TNFα-induced pro-inflammatory cytokine production and adhesion molecule expression.
Adalimumab is a recombinant human IgG1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNF-alpha) and neutralizes its biological activity by blocking its interaction with the p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNF, including changes in adhesion molecules and apoptosis.
400 mg subcutaneously at weeks 0, 2, and 4, then 200 mg every 2 weeks or 400 mg every 4 weeks.
40 mg subcutaneously every 2 weeks; may increase to 40 mg weekly if inadequate response.
None Documented
None Documented
14 days (range 11-17 days) following subcutaneous administration; supports every 2-week or monthly dosing intervals.
Terminal elimination half-life approximately 2 weeks (12-16 days); supports every-2-week dosing in maintenance therapy.
Primarily eliminated via reticuloendothelial system and proteolytic catabolism; no significant renal or biliary excretion. Clinical pharmacokinetic studies show no dose adjustment needed in renal impairment.
Renal: 0.1-0.5% as unchanged drug in urine; biliary/fecal: 70-90% as metabolites; mostly via reticuloendothelial system degradation.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor